All Content Outsourced Pharma

  1. Pioneering Plasmid-IQ™ Design: Accelerating CGT For Faster And More Efficient Solutions 5/13/2025

    Gain insights into the significance of plasmid design in viral vector production, the value of establishing a Plasmid Master Cell Bank (MCB), and the use of analytical assays and Next-Generation Sequencing (NGS) for plasmid verification.

  2. Lilly's CEO Building On The Trump Agenda 5/12/2025

    “We hadn’t built a new site in the U.S. in more than 40 years until the first set of Trump tax cuts, so we need to see those either extended or improved to support this,” Eli Lilly CEO David Ricks recently said, announcing — in Washington, DC — plans to invest $27 billion to build four new manufacturing plants in the U.S.

  3. ADCs Unleashed: Navigating Development Hurdles In Targeted Cancer Therapy 5/12/2025

    Despite their potential to revolutionize treatment paradigms, antibody-drug conjugates (ADCs) face challenges that companies must tackle for successful development.

  4. The Potential Impact Of U.S. Tariffs On The Biotech Sector: Manufacturing, Funding, And Clinical Trials 5/12/2025

    Syner-G Biopharma Group's Raymond Forslund, Ph.D., MBA explores how U.S. tariffs might affect biotech manufacturing, funding, and clinical research.

  5. Global Access To Cell And Gene Therapy: ARM Studios Interview With Boro Dropulić 5/9/2025

    Don’t miss this compelling interview with Boro Dropulić, CEO of Caring Cross, on how the cell and gene therapy sector can turn scientific breakthroughs into global health solutions.

  6. A Case For Paying Allogeneic Cell Therapy Product Donors 5/9/2025

    The debate over whether to pay donors for cell therapy starting materials comes down to four areas of disagreement: altruism, availability, ethics, and safety.

  7. Protecting Intellectual Property In The Genomics Revolution 5/9/2025

    Providing superior IP protection for genomics-related inventions already requires — and will require in the future — a more nuanced strategy combining patents, trade secrets, and copyrights.

  8. April 2025 — CDMO Opportunities And Threats Report 5/8/2025

    Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

  9. Incorporating AI Tools Into Downstream Process Optimization 5/8/2025

    Data-driven, hybrid modeling complements mechanistic thinking by reducing computational load for faster decision-making when time is a critical consideration.

  10. NewBiologix Licenses Xcell-Eng-HEK293 Cell Line To ReciBioPharm For Development And Manufacture Of Adeno-Associated Virus (AAV) Therapeutics 5/8/2025

    NewBiologix, a technology innovation company enabling efficient, cost-effective, and scalable production of viral vectors for cell and gene therapy (C>), today announced it has granted a non-exclusive technology license to ReciBioPharm – Recipharm’s Advanced Therapies (ATMP) division and a leading Contract Development and Manufacturing Organization (CDMO) – to provide global biotech and pharma companies with access to NewBiologix’s Xcell-Eng-HEK293 cell lines.